N/A
Manufactured by Novartis Pharmaceuticals Corporation
6,884 FDA adverse event reports analyzed
Last updated: 2026-04-15
TOBRAMYCIN AND DEXAMETHASONE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Novartis Pharmaceuticals Corporation. The most commonly reported adverse reactions for TOBRAMYCIN AND DEXAMETHASONE include EYE PAIN, OFF LABEL USE, DRUG INEFFECTIVE, HEADACHE, VISION BLURRED. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for TOBRAMYCIN AND DEXAMETHASONE.
Out of 3,126 classified reports for TOBRAMYCIN AND DEXAMETHASONE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 6,884 FDA FAERS reports that mention TOBRAMYCIN AND DEXAMETHASONE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include EYE PAIN, OFF LABEL USE, DRUG INEFFECTIVE, HEADACHE, VISION BLURRED, OCULAR HYPERAEMIA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Novartis Pharmaceuticals Corporation in connection with TOBRAMYCIN AND DEXAMETHASONE. Always verify the specific product and NDC with your pharmacist.